🎉 M&A multiples are live!
Check it out!

Anika Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Anika Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Anika Therapeutics Overview

About Anika Therapeutics

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.


Founded

1992

HQ

United States of America
Employees

288

Website

anika.com

Financials

LTM Revenue $118M

LTM EBITDA $13.7M

EV

$167M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Anika Therapeutics Financials

Anika Therapeutics has a last 12-month revenue of $118M and a last 12-month EBITDA of $13.7M.

In the most recent fiscal year, Anika Therapeutics achieved revenue of $120M and an EBITDA of $3.0M.

Anika Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Anika Therapeutics valuation multiples based on analyst estimates

Anika Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $167M $120M XXX XXX XXX
Gross Profit $93.6M $103M XXX XXX XXX
Gross Margin 56% 86% XXX XXX XXX
EBITDA -$11.2M $3.0M XXX XXX XXX
EBITDA Margin -7% 3% XXX XXX XXX
Net Profit -$14.9M -$82.7M XXX XXX XXX
Net Margin -9% -69% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Anika Therapeutics Stock Performance

As of April 15, 2025, Anika Therapeutics's stock price is $14.

Anika Therapeutics has current market cap of $197M, and EV of $167M.

See Anika Therapeutics trading valuation data

Anika Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$167M $197M XXX XXX XXX XXX $0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Anika Therapeutics Valuation Multiples

As of April 15, 2025, Anika Therapeutics has market cap of $197M and EV of $167M.

Anika Therapeutics's trades at 1.4x LTM EV/Revenue multiple, and 12.2x LTM EBITDA.

Analysts estimate Anika Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Anika Therapeutics and 10K+ public comps

Anika Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $167M XXX XXX XXX
EV/Revenue 1.4x XXX XXX XXX
EV/EBITDA 55.4x XXX XXX XXX
P/E -3.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -57.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Anika Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Anika Therapeutics Valuation Multiples

Anika Therapeutics's NTM/LTM revenue growth is -2%

Anika Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.3M for the same period.

Over next 12 months, Anika Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Anika Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Anika Therapeutics and other 10K+ public comps

Anika Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -28% XXX XXX XXX XXX
EBITDA Margin 3% XXX XXX XXX XXX
EBITDA Growth -127% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 0% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 21% XXX XXX XXX XXX
Opex to Revenue 68% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Anika Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Anika Therapeutics M&A and Investment Activity

Anika Therapeutics acquired  XXX companies to date.

Last acquisition by Anika Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Anika Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Anika Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Anika Therapeutics

When was Anika Therapeutics founded? Anika Therapeutics was founded in 1992.
Where is Anika Therapeutics headquartered? Anika Therapeutics is headquartered in United States of America.
How many employees does Anika Therapeutics have? As of today, Anika Therapeutics has 288 employees.
Who is the CEO of Anika Therapeutics? Anika Therapeutics's CEO is Dr. Cheryl R. Blanchard, PhD.
Is Anika Therapeutics publicy listed? Yes, Anika Therapeutics is a public company listed on NAS.
What is the stock symbol of Anika Therapeutics? Anika Therapeutics trades under ANIK ticker.
When did Anika Therapeutics go public? Anika Therapeutics went public in 1993.
Who are competitors of Anika Therapeutics? Similar companies to Anika Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Anika Therapeutics? Anika Therapeutics's current market cap is $197M
What is the current revenue of Anika Therapeutics? Anika Therapeutics's last 12-month revenue is $118M.
What is the current EBITDA of Anika Therapeutics? Anika Therapeutics's last 12-month EBITDA is $13.7M.
What is the current EV/Revenue multiple of Anika Therapeutics? Current revenue multiple of Anika Therapeutics is 1.4x.
What is the current EV/EBITDA multiple of Anika Therapeutics? Current EBITDA multiple of Anika Therapeutics is 12.2x.
What is the current revenue growth of Anika Therapeutics? Anika Therapeutics revenue growth between 2023 and 2024 was -28%.
Is Anika Therapeutics profitable? Yes, Anika Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.